GU Cancers 2025 | Recent findings on the role of daratumumab in kidney and bladder cancer
Matthew Campbell, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a recent paper on daratumumab, a CD38-targeting monoclonal antibody, in kidney and bladder cancer. A study found that daratumumab influenced the tumour microenvironment (TME) in renal cell cancer (RCC) and muscle invasive bladder cancer through targeting CD38 subsets, despite limited activity. Whilst it is unlikely to have significant activity on its own, it may influence the immune microenvironment (IME) in combination therapies. In a separate trial (NCT03473730), darotumumab-untreated patients after immunotherapy (IO) or tyrosine-kinase inhibitors (TKIs) such as cabozantinib displayed IME depletion, suggesting timing is critical in initiating a favourable cancer response. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
